Manage Your Liver
Q:

A deadly liver disease is on the rise - NASH

A deadly liver disease is on the rise - NASH
A:

NASH (Nonalcoholic Steatohepatitis) is closely linked with NAFLD (Non-alcoholic fatty liver disease). Both of these liver diseases are common, and are often known as silent liver killers. NASH resembles alcoholic liver disease, but occurs in people who drink little or no alcohol at all. The major characteristic of NASH is fat in the liver, along with inflammation and damage. NASH can be severe and can lead to cirrhosis. The number of NASH cirrhosis patients is currently on the rise, and it is predicted (NAFLD & NASH) to be the number 1 cause of liver transplants by 2020. [1]

 

No medication treatment, but there is a great hope

NASH affects 2 to 5 percent of Americans. An additional 10 to 20 percent of Americans have fat in their liver, but no inflammation or liver damage; this condition is called “fatty liver.” Although having some fat in the liver is normal, some people might develop inflammation because of this fat accumulation, this is when it turns into NASH. The reason behind this is still unknown, moreover, there is yet to be an official medicine for NASH, or NASH with cirrhosis. [2]

 

Despite that, YHK Therapy, a formulated compound made from natural ingredients has shown that damaged liver cells can be repaired, and liver damage caused by NASH can be treated. The promising signs shown by the method of preventing liver cell damage have lead pharmaceutical companies to start researching on and developing drugs that have similar function as YHK Therapy. 

 

What is killing the liver?

The death of liver cells and ongoing inflammation is the main cause of many liver diseases. Usually, liver cells are killed by one of two major mechanisms: apoptosis, a form of programmed cell death, or necrosis, which is uncontrolled cell death caused by infection, toxins or trauma. Both of these mechanisms can produce a state of acute and/or chronic inflammation. 

 

Check your ALT

The main marker to determine the degree of liver cell death is the ALT enzyme level, which is tested in liver function tests. ALT is an enzyme that is produced in liver cells and is naturally contained in the liver of healthy individuals. However, in liver disease patients, liver cells are damaged and as a result, ALT is released into the blood, increasing ALT levels to above the normal range. To monitor a patient's liver condition, ALT level is an important clinical biochemical marker of the severity of liver inflammation and the extent of liver disease. [3]

 

Normalise ALT level in days with YHK

ALT is the primary marker for all liver diseases including NASH. Patients with NASH often have high ALT levels, ranging from around 100 to as high as 1000. Normal ALT level should be around 45 to 50, the lower the better. If your ALT level is around the 20-30 range, then you have great liver health.

 

A pilot clinical study of YHK shows that YHK can lower patients’ ALT level within days, and all subjects’ ALT levels were brought back to normal level (under 40) after using YHK for 30 days. No side effect was observed during the use of the natural therapy.

 

If you are currently experiencing NASH, with or without cirrhosis, you are welcome to send us any questions or contact our support team for further information about YHK.

 

The above YHK study was conducted in a university in Canada by PAUL MAROTTA, MD and was later published in the medical journal Digestive Diseases and Sciences 2006 and is currently listed on PubMed.gov. [4]

 

Disclaimer:
  • * All research and clinical data should be used as reference purposes only, results may vary.
Related Questions
A:
Using YHK correctly can have a big affect on the results. In this article, we will explain how you can use YHK at a minimal cost to quickly recover your liver health as well as prevent liver problems in the long run! YHK is made with natural ingredients widely used as functional food in Asian society; its formula is patented in the US. The amount of YHK required is based on liver health status and therefore varies among individuals. A person with more severe liver injury will r
A:
Read Linda's story. ================ “I was diagnosed with a fatty liver and tested for PBC, Primary Biliary Cholangitis and the hepatologist told me there was nothing I could do except to lose weight. I was determined to prove him wrong and researched fatty liver and PBC. I came across your website and ordered the YHK tablets. Since both my AST and ALT were elevated however not extremely high, I only took one tablet upon rising on an empty stomach and one
Hit Questions
A:
Hepatitis C is a wide spread and deadly disease affecting an estimated of 3.5 million Americans.   Treatment for hepatitis C has evolved over the years, going from highly toxic drugs involving injections with horrible side effects, to medications with minimal side effects. Success rate of treatment options has also improved greatly Although the high price tag of the new DAA treatment is controversial, it has undoubtedly helped to cure many hepatitis C patients.
A:
Fibrosis is scarring of the liver that results from chronic inflammation. It is a process where the damaged, dying liver cells are replaced by fibrous scar tissue, causing the liver to become hard. The extent of liver fibrosis can vary, and it is often classified in several stages. The most common classification is a scale from F0 to F4. F0 indicates no fibrosis. A normal liver is at a stage between F0 and F1. F2 denotes light fibrosis, and F3 indicates severe fibrosis. When scar tissue build
A:
You probably have already heard about the new antiviral hep C drug, which is effective but insanely expensive. It claims to have around 90% success rate, that’s why so many hepatitis C patients are dying for it even though it’s extremely costly. But apart from its expensive price tag, there is a bigger issue behind this new drug that not many people know about. Scientists and researchers have found an increased risk of extreme liver cancer related to this new drug after successful
A:
Hepatitis C viruses share a common characteristic to other chronic liver diseases; it could damage the patients’ liver cells. Hepatitis C patients should focus on stopping or reducing the damage in the liver, and this focus should be the same for other chronic liver diseases e.g. hepatitis B, fatty liver disease, NASH etc. And this is exactly what YHK can do.   YHK can stop liver cells damage caused by hepatitis viruses, and can repair damaged liver cells, to he
YHK Liver Therapy
Your Liver
Protection

starts here.
Buy YHK
Have Questions?
Sumbit your question to us for profeessional answers!
Looking for help? Ask our customer support team!
Contact Us